Pur pose. The feasibility of hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor-a (TNFa ) and cisplatin for the m anagement of osteosarcoma was studied in the canine m odel. M ethods. During seven perfusions in six healthy mongrel dogs (weight 32±2 kg) technical aspects of HILP under mild hyperthermia (39± 40Ê C) were studied. In ® ve experim ents HILP was perform ed with TNFa alone (0.5 mg/l extremity volume), and in two experiments TNFa was combined with cisplatin (25 mg/l extrem ity volume). During the perfusions physiological parameters were m onitored and TNFa and total cisplatin concentrations were determined. Results. Perfusion conditions (pH, PCO 2 , PO 2 ,¯ow and pressure) rem ained within physiological ranges. Three dogs died within 24 h despite a sublethal systemic concentration of TN Fa that leaked from the perfusion circuit. Three dogs were terminated; one dog after the second experiment in accordance with Dutch ethical rules; one dog showed an invagination of the small bowel resulting in an ileus; one dog because of necrosis of the perfused limb.
Introduction
Osteosarcom a is the m ost frequent prim ary m alignant bone tum or in hum ans. Until the 1970s the m ost com m on approach to the m anagem ent of localized osteosarcom a was surgical resection, am putation or radiation therapy.
1 D uring the last decades a de® nite role for neoadjuvan t high-dose m ethotrexate and cisplatin-based polychem otherapy was established. T he p otential lo cal tum or effect of system ically adm inistered cisplatin, however, is lim ited due to the nephrotoxicity and ototoxicity of cisplatin. T herefore an attem pt was m ade to increase the local effect of cisplatin without increasing system ic toxicity by using hyperthermic isolated regional lim b perfusion (HILP) with cisplatin in dogs w ith spontaneous osteosarcom a. 5 T hese studies showed an acceptable locoregional toxicity, im proved functional outcom e at 6 and 12 weeks, and a steadily im proving radiological picture. However, the histological results were modest, with none of the dogs showing a com plete response at 6 weeks after perfusion. T he sam e experience was found in patients with sarcom as of soft tissue and bone treated w ith cisplatin H ILP. 6 Results of recent publications and of our own experience w ith a new perfusion m odality, which com bines tum or necrosis factor-a (TN F a ) and m elphalan in patients w ith recurrent m elanom a or soft tissue sarcom a, are very prom ising. 7, 8 H owever, in six of eight evaluable patients with unresectable osteosarcom a of the lower lim b treated w ith T N F a an d m elp halan H IL P, histological evaluation revealed m oderate results with 80% necrosis in three patients, 50± 60% necrosis in two patients and < 50% necrosis in one patient. After TN F a and m elphalan H ILP, lim b spar ing surgery was possible in six patients. 9 As cisplatin is one of the m ost active chem otherapeutics in the treatm ent of osteosarcom a, it seems worthwhile to investigate the results of HILP with T N Fa and cisplatin. W ith the high frequency of occurrence in dogs, canine osteosarcom a is a useful m odel for evaluation of new treatment regim ens in humans as rapid case accrual and rap id tim e to reach m easu rable en d p oin ts are possible. 10 T he canine osteosarcom a therefore appears to be a valid m odel for studying the potential treatment of H IL P with T N Fa and cisplatin in the local treat m en t o f osteo sarco m a o f th e extrem ity in hum ans. To establish optim al HILP conditions using TN Fa and cisplatin for local tum or control in dogs bearing osteosarcom a, a feasibility study in healthy dogs was undertaken.
Materials and m ethods

Dogs
During seven experim ents in six healthy m ongrel dogs with a m ean average weight of 32 ± 2 kg and a m ean age of 6 ± 1 years, different asp ects of HILP with TN Fa and cisplatin were studied. Preoperatively, all dogs w ere tho rou ghly clin ically evaluated at the Central Anim al Facility of the University of G roningen.T he study was approved by the Anim al Welfare Comm ittee of the Faculty of M edicine of the G roningen U niversity.
Anaesthetics
The dogs fastened for 12 h and were anaesthetized with thiopental (30 m g/kg body w t., i.v.) (Pentothal, Abbott, Am stelveen, T he N etherlands) and, after m u scle rela xatio n w ith p a n cu ro n iu m b ro m id e (0.08 m g/kg body w t., i.v.) (Pavulon, Organon, O ss, The N etherlands), the dogs were ventilated (Ohm eda Modulus 2) with a mixture of O 2 and iso¯urane. T he oxygen concentration in the gas m ixture was continuously m easured by m ean s of an oxygen analyzer (Ohm eda M odulus 2) and m inute volum es (4± 6 l/ min) were adjusted to maintain an end-expirator y CO 2 concentration of 4± 5% (Siem ens C O 2 analyzer 930). The dogs were placed in the supine position on a heated m attress to m aintain their norm al body tem perature of 38Ê C. 11 D uring the operations all dogs were given about 2 l of glucose 5% via a cephalic or internal jugular vein. C entral arterial pressure was recorded as well as an EC G and diuresis.
Operation and perfusion techniques
D uring anaesthesia the volum e of the extrem ity was measured using Archim edes' rule (1.7± 2 l). T he iliac vessels were exposed under sterile conditions and collateral vessels were clipped. C annulas were inserted into the artery (Bardic, 14± 18 F ) and vein (Bardic, 14± 18 F ). B o th can nu las were con n ected to an extracorporeal circuit consisting of an occlusive roller pump, a cardiotomy reservoir and a bubble oxygenator with heat-exchanger. A tourniquet m ade of nylon was placed around the base of the extrem ity, using a pin in the bone and a bandage around the m iddle to com plete the isolation of the limb from the system ic circulation. T he perfusate consisted of 350 m l 5% dextran 40 in glucose 5% (Isodex, Pharm acia AB, U ppsala, Sweden), 250 ml red blood cells ( (0.5 m g/l extremity volum e) (Boehringer, Ingelheim , G erm any) was calculated in order not to exceed ten tim es th e accep tab le system ic levels (system ic , 10 m g/kg body wt). 14 The dosage of cisplatin (20 m g/l extremity volum e) (Platinol 0.5 m g/m l, Bristol M yers S q u ib b , Weesp, T h e N eth erlan d s) u sed in th e perfusion had been established in a previous study and was based on a m axim um tolerable dose of 30 m g/l extremity volum e. 15 C isplatin was added to the circulated perfusate in 10 min. D uring perfusion, ser u m T N F a an d to tal cisp latin levels w ere determ ined in the regional and system ic circulation at 0, 5, 15, 30, 45, 60, 75 and 90 m in by EL ISA and am eless ato m ic ab so r p tio n sp ecto p ho to m etr y (FAAS), respectively. The perfusion time was 1 h, followed by wash-o ut of the extrem ity with 3 l of Isodex. Tourniquet, cannulas and clips were then rem oved and the incisions in the vessels repaired. P ro tam in e hyd ro ch lo r id e (H o ff m a n L a R o ch e, M ijdrecht, The N etherlands) was adm inistered, to neutralize heparin, in a ratio of 1:1 to the initial dose of heparin. All dogs were closely observed for at least 24 h. N o anti-in¯am m atory or analgesic drugs were adm inistered during follow-up.
All dogs were followed for local and system ic side effects of TN Fa and cisplatin perfusion, as well as sur vival. Table 1 show s the characteristics of the seven experim ents in six dogs. D uring the experim ents conditions for perfusions (pH , PCO 2 , PO 2 ) were kept within the physiolo gical ranges, as in hum an perfusions. Figure  1 shows the¯ow, blood pressure, perfusion pressures, weight gain or loss of the extracorporeal circuit and temperature during 60 m in of perfusion in the seven experim ents. In the ® rst ® ve experim ents, only T N Fa was adm inistered to the perfusion circuit. In the last two experim ents cisplatin was added. Table 1 . T hree dogs died within 24 h: the ® rst two during the T N Fa experim ent; the third after T N Fa and cisplatin perfusion. Postm ortem exam ination of these an im als d id n o t p rov id e an y m acro sco pic o r m icroscopic evidence to explain the cause of death. T hree dogs were term inated; two due to treatm ent com plications. O ne dog showed an invagination of the sm all bowel, resulting in an ileus and another was terminated 1 week after TN Fa and cisplatin perfusion because of necrosis of the perfused lim b. T he third dog was term inated after the second experim ent in accordance with D utch ethical rules.
Results
Discussion
In the treatment of osteogenic sarcom a a distinction can be m ade between system ic therapy and locoregion al treatm en t. Before application of TN F a and cisplatin HILP in humans and client-owned osteosarcom a-bearing dogs, the present feasibility study was perform ed in norm al healthy dogs. D espite sufficient experience in H ILP in dogs as well as in hum ans, an unexpected high m ortality rate was encountered. Although there was no m ortality related to the operation, three dogs died w ith in 24 h a fter p erfu sio n (50 % ). T h is d irect postoperative m ortality could not be explained by a surplus of system ical leakage of TN F. In the experim ent, the dog w ith the highest leakage and, as a 
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; Grade I, no reaction, objectively and subjectively; Grade II, slight erythema, oedem a or loss of sensation; G rade III, considerable erythema or oedema with some blistering, slight functional disturbances; G rade IV, extreme epiderm iolysis and/or obvious damage to the deep tissues causing de® nite functional disturbances; Grade V, reaction that might necessitate amputation.
consequence, the highest system ic T N Fa concentrations, survived im m ediately postoperatively, and the dog with the lowest leakage (lowest system ic T N Fa concentrations) died within 24 h after perfusion. N o correlation between leakage and m ortality rate could be established. M axim al leakage encountered in these experim ents was 33% , this corresponds to 330 m g T N Fa given system ically per dog; since the average dog weighs 33 kg, the dose of T N Fa that reaches the system ic circulation of the dog is sublethal (10 m g/ kg).
14 Although only sublethal doses of T N Fa leaked to the system ical circu lation , the clin ical picture resem bled respon se s o bse r ved w ith leth al do se s ( > 1 00 m g /k g) , ch a ra cter iz ed b y p ro g re ssive 
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